Adam Crystal - 01 Jul 2021 Form 4 Insider Report for C4 Therapeutics, Inc. (CCCC)

Role: Chief Medical Officer
Signature: /s/ Shoaib Ghias, Attorney-in-Fact
Issuer symbol: CCCC
Transactions as of: 01 Jul 2021
Net transactions value: -$472,166
Form type: 4
Filing time: 06 Jul 2021, 20:00:26 UTC
Next filing: 02 Aug 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CCCC	Common Stock	Options Exercise	$97,500	+15,000		$6.50	15,000	01 Jul 2021	Direct	F1
transaction	CCCC	Common Stock	Sale	$504,420	-13,300	-89%	$37.93^*	1,700	01 Jul 2021	Direct	F1, F2
transaction	CCCC	Common Stock	Sale	$65,246	-1,700	-100%	$38.38^*	0	01 Jul 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CCCC	Stock Option (Right to Buy)	Options Exercise	$0	-15,000	-9.5%	$0.000000	142,292	01 Jul 2021	Common Stock	15,000	$6.50	Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on January 21, 2021.
F2	The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.33 to $38.25. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3	25% of this option vested and became exercisable on February 14, 2020, with the remainder vesting in 16 equal quarterly installments thereafter.